Eli Lilly and Company $LLY Shares Acquired by Community Financial Services Group LLC

Community Financial Services Group LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 13.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,029 shares of the company’s stock after purchasing an additional 1,303 shares during the quarter. Eli Lilly and Company comprises about 1.5% of Community Financial Services Group LLC’s holdings, making the stock its 21st largest position. Community Financial Services Group LLC’s holdings in Eli Lilly and Company were worth $8,415,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC lifted its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in Eli Lilly and Company by 499.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 18,088 shares of the company’s stock worth $14,939,000 after purchasing an additional 15,071 shares during the period. Petrus Trust Company LTA purchased a new position in Eli Lilly and Company during the first quarter worth approximately $425,000. Finally, Raab & Moskowitz Asset Management LLC boosted its holdings in Eli Lilly and Company by 3.1% in the first quarter. Raab & Moskowitz Asset Management LLC now owns 1,996 shares of the company’s stock valued at $1,649,000 after acquiring an additional 60 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a research note on Monday, November 10th. BMO Capital Markets set a $1,200.00 target price on Eli Lilly and Company in a research note on Thursday, December 4th. Wolfe Research increased their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Five research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,079.83 on Monday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a 50-day simple moving average of $1,013.16 and a 200 day simple moving average of $851.29. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The company has a market cap of $1.02 trillion, a PE ratio of 52.83, a P/E/G ratio of 0.78 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company earned $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 33.86%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.